Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04386317 · ClinicalTrials.gov registry record · Phase 2

Terazosin Effect on Cardiac Changes in Early Parkinson's Disease

A Phase 2 study of REM Sleep Behavior Disorder and Symptomatic Parkinson Disease, sponsored by Cedars-Sinai Medical Center.

Active
Registry status
Phase 2
Development phase
15
Enrollment target
1
Study location

NCT04386317 is a Phase 2 study of REM Sleep Behavior Disorder and Symptomatic Parkinson Disease that is active but no longer recruiting, run by Cedars-Sinai Medical Center. The registered enrollment target is 15 participants, below the 156-participant average among 11 other REM Sleep Behavior Disorder trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04386317, a Phase 2 study of REM Sleep Behavior Disorder and Symptomatic Parkinson Disease, is active but no longer recruiting, sponsored by Cedars-Sinai Medical Center.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
15 participants
Enrollment target
1
Study location

Study Summary

Parkinson's disease (PD) is characterized by many non-motor symptoms that occur several years before the diagnosis, in particular idiopathic REM behavior disorder (iRBD), which is associated with autonomic impairment. The purpose of this study is to investigate the effect of treatment with the selective post-synaptic a1-adrenergic blocker terazosin on 123I-MIBG myocardial uptake in a population of subjects with defined pre-motor PD risks (i.e. hyposmia and RBD) and abnormal baseline 123I-MIBG uptake, with or without 123I-Ioflupane uptake abnormality or PD motor symptoms. Scintigraphic changes will be correlated to motor and non-motor severity of PD, measured by validated clinical scales and cardiac autonomic function tests.

Conditions Studied

REM Sleep Behavior Disorder Symptomatic Parkinson Disease Pre-motor Parkinson's Disease

Interventions

  • DRUG Terazosin

Study Locations (1)

California

  • Michele L Lima Gregorio - Los Angeles

Trial Details

FieldValue
Enrollment Target 15 participants
Start Date 2020-11-01
Est. Completion 2026-03-10
Phase Phase 2

Sponsor

Cedars-Sinai Medical Center

339 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04386317

The ClinicalTrials.gov registry entry for NCT04386317 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 156-participant average among 11 other REM Sleep Behavior Disorder trials with a reported enrollment target (90% lower). The listed sponsor is Cedars-Sinai Medical Center, which has 339 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with REM Sleep Behavior Disorder appearing as the primary indexed condition, and to 1 intervention - of which Terazosin is the first listed.

NCT04386317 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT04386317 about?

NCT04386317 is a clinical study titled "Terazosin Effect on Cardiac Changes in Early Parkinson's Disease". Parkinson's disease (PD) is characterized by many non-motor symptoms that occur several years before the diagnosis, in particular idiopathic REM behavior disorder (iRBD), which is associated with autonomic impairment. The purpose of this study is to investigate the effect of treatment with the selec...

What is the current status of trial NCT04386317?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2020-11-01. Estimated completion is 2026-03-10.

What conditions does trial NCT04386317 study?

This clinical trial studies the following conditions: REM Sleep Behavior Disorder, Symptomatic Parkinson Disease, Pre-motor Parkinson's Disease.

What interventions are being tested in trial NCT04386317?

The interventions under investigation include: Terazosin (DRUG).

Who is sponsoring clinical trial NCT04386317?

This trial is sponsored by Cedars-Sinai Medical Center, which has 339 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04386317 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for REM Sleep Behavior Disorder

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

REM Sleep Behavior Disorder

All registered trials for this condition

Symptomatic Parkinson Disease

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.